

**REDX PHARMA PLC**  
**("Redx" or "the Company")**

**Result of Annual General Meeting**

**Alderley Park, 8 March 2022** Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, today announces that its Annual General Meeting was held at 11am on 8 March 2022, with all resolutions passed by substantial majorities.

The table below sets out the details of the votes put to shareholders

Resolution number	Resolution name	Number of votes for & discretionary	% of votes for & discretionary	Number of votes against	% of votes against	% of votes withheld	Total votes cast (including withheld)
1	Receive the Company's annual accounts	249,366,792	94.84%	13,571,429	5.16%	0.00%	262,939,628
2	Re-appoint Ernst & Young as auditors	262,938,221	100%	0	0.00%	0.00%	262,939,628
3	Elect Natalie Berner as a director	262,938,221	100%	0	0.00%	0.00%	262,939,628
4	Elect Dr Jane Griffiths as a director	262,938,221	100%	0	0.00%	0.00%	262,939,628
5	Elect Dr Robert Scott as a director	262,938,221	100%	0	0.00%	0.00%	262,939,628
6	Re-elect Dr Thomas Burt as a director	262,938,221	100%	0	0.00%	0.00%	262,939,628
7	Re-elect Sarah Gordon Wild as a director	249,366,792	94.84%	13,571,429	5.16%	0.00%	262,939,628
8	Re-elect Peter Presland as a director	249,366,792	94.84%	13,571,429	5.16%	0.00%	262,939,628
9	Authorise the directors to allot shares	262,936,468	100%	853	0.00%	0.00%	262,939,628
10	Disapply pre-emption rights	262,923,468	99.99%	13,853	0.01%	0.00%	262,939,628

**For further information, please contact:**

**Redx Pharma Plc**  
[ir@redxpharma.com](mailto:ir@redxpharma.com)

T: +44 (0)1625 469 918

**UK Headquarters**  
Lisa Anson, Chief Executive Officer

**US Office**  
Peter Collum, Chief Financial Officer

**SPARK Advisory Partners (Nominated Adviser)**  
Matt Davis/ Adam Dawes

T: +44 (0)203 368 3550

**WG Partners LLP (Joint Broker)**  
Claes Spång/ David Wilson/Satheesh Nadarajah

T: +44 (0)203 705 9330

**Panmure Gordon (UK) Limited (Joint Broker)**  
Rupert Dearden/ Freddy Crossley/ Emma Earl

T: +44 (0)207 886 2500

**FTI Consulting**  
Simon Conway/ Ciara Martin

T: +44 (0)203 727 1000

**About Redx Pharma Plc**

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase 2 programme in November 2021. The Company's selective ROCK2 inhibitor product candidate, RXC007,

is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical trial in June 2021. Initial results were reported in October 2021, with full Phase 1 results expected in 2022.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology and RXC006, a Porcupine inhibitor targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF), which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals.

To subscribe to Email Alerts from Redx, please visit [www.redxpharma.com/investor-centre/email-alerts/](http://www.redxpharma.com/investor-centre/email-alerts/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGUPUBPWUPPGPR